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Background: We aimed at investigating the outcomes of female patients with stage IIIB-IV adenocarcinoma of the
lung according to EGFR and K-Ras mutational status.
Methods: One hundred and three consecutive female patients genotyped at a single Italian Institution were
analyzed. Patients were planned to receive first-line platinum-based chemotherapy (CT) and a salvage treatment
with anti-EGFR tyrosine-kinase inhibitors (TKIs) was proposed irrespective of tumor mutational status. EGFR (exons
18–21) and K-Ras (exon 2, codons 12–13) mutations were evaluated by real-time PCR and pyrosequencing. The
association of mutational status with clinical variables and treatment benefit was investigated by chi-square test
and log-rank test.
Results: EGFR and K-Ras mutations were found in 31 (30%) and 13 (15%) cases, respectively. Sixty-six patients
received platinum CT: no correlation was observed between EGFR or K-Ras mutational status and response rate (RR)
(p > 0.05). However, patients treated with first-line CT harboring EGFR activating mutations experienced a significantly
reduced progression-free survival (PFS) in comparison with wild-type ones (4.4 vs. 6.4 months, respectively; HR 0.597,
95% CI 0.287-0.975; p = 0.048). Thirty-nine patients received salvage treatment with erlotinib: EGFR activating mutations
were significantly correlated with RR (60% vs. 12.5%; p = 0.004) and PFS (11.4 vs. 4.5 months; HR 0.491, 95% CI 0.216-0.936;
p = 0.044). Responses to erlotinib were not reported among women with K-Ras mutant tumors, while 50% of those with
wild-type K-Ras achieved an objective remission (p = 0.296). Median PFS (3.5 vs. 8.8 months; HR 0.284, 95% CI 0.015-0.510;
p = 0.010) and OS (3.9 vs. 19.8 months; HR 0.158, 95% CI 0.001-0.075; p < 0.001) were significantly shorter among K-Ras
mutant patients treated with TKI.
Conclusions: In our population of Caucasian women with advanced lung adenocarcinoma we observed that the
presence of EGFR activating mutations correlates with a significant reduction in the benefit from first-line platinum-based
CT, emphasizing the importance of an upfront use of anti-EGFR TKIs in this patient subset. K-Ras mutations seem to
correlate with a detrimental effect from anti-EGFR TKI, but this finding deserves further investigation.
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The epidermal growth factor receptor (EGFR) and K-Ras
are among the most investigated molecular drivers in solid
tumors. In particular, EGFR is addressed as an interesting
target for several biologic agents, mainly monoclonal anti-
bodies (acting at the cellular surface level) and small mole-
cules (inhibiting the intracellular tyrosine-kinase domain
activity) [1]. EGFR overexpression often correlates with a
worse prognosis is several tumors [2] and the blockade of
the EGFR-driven cascade has been proved successful in
non-small cell lung cancer (NSCLC), colorectal, head and
neck and breast cancer [1]. Mutations in K-Ras, occurring
at different levels along the gene sequence, have been de-
scribed in multiple malignancies [3]. Moreover, K-Ras has
been the first predictive biomarker identified and routinely
used in advanced colorectal cancer management: mu-
tations in this key oncogene predict the benefit from
the anti-EGFR monoclonal antibodies panitumumab
and cetuximab [4], and the role of mutations in different
Ras family members (such as N-Ras) is rapidly emerging
as an essential tool for patient selection in this disease [5].
NSCLC in women is a growing health concern in
Western countries [6]. Gender-related factors (modulating
smoking-dependent and independent carcinogenesis) may
contribute to this increased incidence [7]. The disease is
reported as a peculiar pathological and molecular entity:
in particular, women are more often affected by lung
adenocarcinoma and the tumor arises among never- or
light-smokers with higher frequency than in men [7].
Following the observation that female gender was one
of the clinical features associated with a benefit from
anti-EGFR tyrosine-kinase inhibitors (TKIs) (together
with Asian origin, adenocarcinoma histology and smok-
ing habits) [8,9], deeper insights into the EGFR biology
allowed to identify somatic mutations in the kinase do-
main of the EGFR gene [10]. Nowadays, EGFR mutational
status is a well-recognized predictive factor for anti-EGFR
TKIs activity and an essential tool for treatment allocation
in advanced lung adenocarcinoma [11].
However, the impact of first-line platinum-based chemo-
therapy (CT) in female patients with EGFR mutated adeno-
carcinoma is a matter of debate and no definitive data
emerge from subgroup analyses of randomized trials com-
paring CT with TKIs in the first-line setting [8]. The results
of a recent meta-analysis of prospective and retrospective
studies suggest that EGFR mutations may be associated
with higher response rate (RR) to CT, but may not predict
the benefit of CT with regard to progression-free survival
(PFS) and overall survival (OS) [12].
Among the other molecular aberrations involved in
NSCLC progression, K-Ras is certainly one of the most
extensively studied [13]: K-Ras mutations (mainly located
in codons 12 and 13 of exon 2) are reported in up to 30%
of NSCLC cases [13,14], especially among smokers. It isworth noting that EGFR and K-Ras mutations are rarely
found in the same tumor, suggesting that they may drive
functionally different carcinogenetic processes [13,14].
Direct targeting of K-Ras has recently raised some con-
cerns, as this represents a key transduction pathway in
both normal and tumor tissues. Moreover, several parallel
escape mechanisms have been identified [15]. Moving
from these considerations, alternative targeting of K-Ras is
currently under evaluation, e.g. by inhibiting BRAF or
MEK activity [15].
Inconclusive evidence exists about the role of K-Ras
mutations in predicting the benefit of CT in lung adeno-
carcinoma [16]. On the other hand, retrospective sub-
group analyses seem to suggest that patients with K-Ras
mutated tumors show a primary resistance to anti-EGFR
TKIs [14]. Two meta-analyses demonstrated that the ob-
jective RR to anti-EGFR TKIs in K-Ras mutated tumors
is inferior to wild-type ones [17,18]. However, no defini-
tive conclusion was reported in terms of PFS and OS.
In our clinically enriched series (Caucasian women with
lung adenocarcinoma) we aimed at investigating the pos-
sible predictive significance of EGFR and K-Ras mutations
with respect to both first-line platinum-based CT and sal-
vage treatment with the anti-EGFR TKI erlotinib.
Methods
Eligibility criteria
We retrospectively identified consecutive women with
histologically or cytologically confirmed stage IIIB-IV
adenocarcinoma of the lung treated at five Italian Insti-
tutions between 2007 and 2010. All patients had their
tumor samples available for centralized molecular de-
terminations and were included in the descriptive ana-
lyses of mutation frequency. Patients who had received
any first-line platinum-based combination regimen for
advanced disease and had undergone tumor evalua-
tions were included in the correlative analyses for re-
sponse and survival.
Pre-treatment evaluation included: clinical history, phys-
ical examination, complete blood cell count and biochemis-
try, computed tomography scan of the chest and computed
tomography scan or ultrasonography of the abdomen. Pa-
tients with central nervous system (CNS) metastases were
considered eligible if they were asymptomatic or stable at
imaging evaluation performed 1 month after the comple-
tion of brain radiotherapy.
Treatment
Any platinum-containing regimen was allowed as up-
front therapy: CT was administered for a maximum of
6 courses in responding patients and no maintenance
treatment was administered. Salvage treatment with erloti-
nib 150 mg/die orally was given on the basis of clinician’s
choice according to initial marketing indications of this
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tween erlotinib and CT was driven by clinical factors
(i.e. performance status, organ function, life expect-
ancy, tolerance and response to previous CT). Best
supportive care alone was offered to patients with re-
duced life expectancy (<4 weeks), compromised liver,
kidney or bone marrow function, and deteriorated per-
formance status.
Anti-EGFR TKI treatment was administered until
progression, unacceptable toxicity or patient refusal. Re-
staging during treatment was planned every 12 weeks and
objective responses were evaluated according to the Re-
sponse Evaluation Criteria for Solid Tumors (RECIST)
v. 1.0 [19]. All the responses and progressions were retro-
spectively evaluated by the investigators and no independ-
ent revision was performed.
Written informed consent for treatment, molecular ana-
lyses and data collection was obtained from each patient
according to local Institution policies.
The Ethics Committee of Area Vasta Nord--‐Ovest
approved the study.
Mutational analysis
Microdissection and DNA extraction
Serial 5-μm sections were taken from formalin fixed
paraffin embedded (FFPE) tissues. The last section was
stained with hematoxilin-eosin (H&E), the tumor area
was marked and the percentage of tumor cells was esti-
mated by a pathologist. The tumor tissue was manually
microdissected from one to three unstained sections
previously submitted to xylene deparaffination, and was
lysed overnight at 56°C in 180 μl of ATL buffer and
20 μl of proteinase K (QIAGEN, Hilden, Germany).
DNA was purified using the spin column procedure
(QIAamp minikit; QIAGEN) and finally reconstituted
in 40 μl of AE buffer. DNA content was measured with
a Nanodrop-1000 spectrophotometer (Thermo Fisher
Scientific Inc. Waltham, MA) and was kept at 4°C be-
fore use.
Detection of EGFR mutations by PCR single-strand
conformation polymorphism (SSCP) and direct DNA
sequencing
EGFR mutation analysis was performed by amplifying
exons 18 to 21 as follows. 5 μL of genomic DNA concen-
trated 20 ng/μL was amplified in a 25-μl PCR mixture
containing 12.5 μL of HotStarTaq Master Mix Kit (QIA-
GEN) and 0.5 μL of 20 uM forward and reverse primers.
All reactions were done in duplicate. The following PCR
primers for EGFR exons 18–21 were used:
for exon 18, 5′(Fw)-CTCTGTGTTCTTGTCCCCCC-3′
and 5′(Rev)-GCCTGTGCCAGGGACCTTAC-3′
(amplicon size, 166 bp);for exon 19, 5′(Fw)-CATGTGGCACCATCTCACA-3′
and 5′(Rev)-CCACACAGCAAAGCAGAAAC-3′
(amplicon size, 179 bp);
for exon 20, 5′(Fw)-CACACTGACGTGCCTCTCC-3′
and 5′(Rev)-TATCTCCCCTCCCCGTATCT-3′
(amplicon size, 250 bp);
for exon 21, 5′(Fw)-CCTCACAGCAGGGTCTTCTC-3′
and 5′(Rev)-AATGCTGGCTGACCTAAAGC-3′
(amplicon size, 215 bp).
A mock control with no addition DNA was processed
in parallel with each sample. Cycling conditions were as
follows: initial denaturation (95°C, 15 min), then 40 cycles
of denaturation (95°C for 30 sec), annealing (58°C for
60 sec) and synthesis (72°C for 60 sec). All PCR products
were visualized by electrophoresis on a 1.5% agarose gel
stained with ethidium bromide. All PCR products were
then diluted 1:1 with denaturing solution (1% xylene cya-
nol, 1% bromophenol blue, 0.1 mM EDTA and 99% form-
amide), denatured at 95°C for 5 min and immediately
placed on ice to prevent annealing of the single-strand
products. SSCP was carried out on a GenePhor Electro-
phoresis Unit using GeneGel Excel 12.5/24 (12.5% T, 2%
C) (GE Healthcare Biosciences AB, Uppsala, Sweden), ac-
cording to the manufacturer’s instructions. Electrophor-
esis (600 V, 25 mA, 15 W) was performed at 18°C for
100 min. Gels were stained with the DNA Silver Staining
Kit (GE Healthcare Biosciences AB), according to the
manufacturer’s instructions. Altered migrations patterns
in two independent PCR-SSCP runs were indicative of
DNA mutations. All PCR products were purified with
QIAquick PCR Purification kit (QIAGEN) and labeled
using the BigDye Terminator (version 3.1) Cycle Sequen-
cing Kit (Applied Biosystems, Foster City, CA, USA) ac-
cording to the manufacturer’s protocol, and were followed
by sequencing in an ABI 3130 Genetic Analyzer (Applied
Biosystems). Both forward and reverse sequencing re-
actions were performed with the same PCR primers at
0.8 μmol/L in a final volume of 20 μL. The sequencing
data were visualized using of Sequencing Analysis (Applied
Biosystems), and were independently evaluated by two
investigators.
Detection of K-Ras mutation by pyrosequencing
The K-Ras codons 12/13 mutational analysis was evaluated
amplifying 5 μL of genomic DNA concentrated 20 ng/μL
by Anti-EGFR MoAb response® (KRAS status) CE-IVD
marked kits (DIATECH Pharmacogenetics, Italy) on
Rotor-GeneTM 6000 (Corbett Research, Australia) follow-
ing the manufacturer’s instructions. The resulting PCR
product was immobilized onto magnetic streptavidin-
coated beads via the biotin/streptavidin interaction. The
bead/DNA complex was then washed and added to 1.65
pmol of pyrosequencing primer included in the same kit.
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transferred to the microtitre plate-based PSQ HS 96 A
Pyrosequencer (Biotage, Sweden), where real-time sequen-
cing of the sequence surrounding codon 12/13 exon 2 of
K-Ras was performed by using PyroMark Gold Q96 re-
agents (QIAGEN) on PyroMarkTM Q96 ID instrument
(Biotage). The results were analyzed using PyroMark Q24
1.0.9 software, and were independently evaluated by two
investigators.
Statistical analysis
EGFR and K-Ras mutations were correlated with clinical
features such as smoking habits (never or former vs.
current smokers) and brain metastases (yes vs. no) by
means of the chi-square test.
The primary endpoints for correlative analyses were
PFS times after first-line CT and salvage treatment with
erlotinib. RR and OS were secondary endpoints.
PFS was calculated from the start of first-line CT or
salvage erlotinib to the date of disease progression or
death (whichever occurred first). OS was calculated from
the start of first-line CT or salvage erlotinib to the date
of death or last follow up visit. PFS and OS were esti-
mated using the Kaplan-Meier method. Differences
across curves were analyzed by log-rank test, while cor-
relation with RR was estimated using the chi-square test.
Statistical significance was set at p < 0.05 for a two-tailed




A total of 103 women were identified and included in
the descriptive analysis. Sixty-six patients, who received
first-line platinum-based CT and whose clinical and mo-
lecular data were available, were included in the correla-
tive analysis. The main characteristics are summarized
in Table 1.
EGFR and K-Ras mutations: correlation with clinical
variables
EGFR and K-Ras mutations were found in 30% and 13%
of the cases, respectively (Table 2): in this series muta-
tions in EGFR and K-Ras were mutually exclusive. EGFR
mutations were exon 19 deletion (77%), exon 21 L858R
mutation (13%) and exon 20 mutation (10%). Among
the K-Ras mutant cases, 77% and 23% had mutations
in codons 12 and 13, respectively.
K-Ras mutations were significantly associated with
smoking history: indeed, mutations were more frequent in
current smokers compared to former or never smokers
(28% vs. 8%; p = 0.024). On the contrary, EGFR mutations
occurred more frequently in never smokers, although thedifference did not reach statistical significance (35% vs.
19%; p = 0.108).
In our series, there was no correlation between EGFR
(mutant vs. wild-type: 13% vs. 15%; p = 1.000) or K-Ras
(mutant vs. wild-type: 0% vs. 18%; p = 0.208) status and
the development of CNS metastasis during the clinical
course of the disease.
At a median follow up of 46.7 months, 97% of the pa-
tients had progressed after first-line CT and 55% had
died.
EGFR and K-Ras mutations: correlation with benefit from
first-line CT
Sixty-six patients were treated with first-line platinum-
containing CT. When the EGFR mutational status was
considered, a significantly longer median PFS was observed
among women with wild-type tumors than among women
harboring mutant tumors (6.4 vs. 4.4 months, respectively;
HR 0.597, 95% CI 0.287-0.975; p = 0.048) (Figure 1A). As
regards K-Ras status, no significant difference was ob-
served between wild-type and mutant patients in terms of
median PFS (5.3 vs. 5.0 months, respectively; HR 1.041,
95% CI 0.497-2.189; p = 0.914) (Figure 1B). When add-
itional prognostic factors were analyzed (age, smoking
habits, stage of disease, type of EGFR mutation), none was
significantly associated with PFS (Table 3).
As regards RR, 26 (40%) achieved an objective response,
20 (30%) reported disease stabilization and 20 (30%) pro-
gressed during CT. Neither EGFR nor K-Ras mutations
significantly correlated with response to first-line CT: RR
was 32% vs. 43% in EGFR mutant vs. EGFR wild-type
tumors (p = 0.579), and 33% vs. 39% in K-Ras mutant vs.
K-Ras wild-type tumors (p = 1.000), respectively. No sta-
tistically significant differences in median OS were ob-
served according to EGFR mutational status (wild-type
vs. mutant: 29.5 vs. 26.2 months; HR 0.967, 95% CI
0.473-1.974; p = 0.926) or K-Ras (wild-type vs. mutant:
26.1 vs. 26.8 months; HR 0.877, 95% CI 0.342-2.207;
p = 0.771).
EGFR and K-Ras mutations: correlation with benefit from
salvage erlotinib
Thirty-nine (59%) women received salvage treatment
with erlotinib. At the time of the analysis, 74% progressed
and median PFS for the entire population was 7.2 months.
We observed a trend toward a higher benefit from erloti-
nib when administered in second line compared to third
or fourth line (10.0 vs. 4.0 months, respectively; HR 0.587,
95% CI 0.206-1.145; p = 0.132): this difference was less evi-
dent when the analysis was restricted to EGFR mutant pa-
tients (12 and 3 patients for second-line and ≥ third-line
treatment, respectively: 11.4 vs. 24.2 months). Unfortu-
nately, five patients with EGFR mutant tumors experi-
enced rapid worsening of general conditions after first-line
Table 1 Patient demographic and clinical characteristics
Descriptive cohort (n = 103) Correlative cohort (n = 66) Anti-EGFR treated (n = 39)
n % n % n %
Age (years)
Median 64 60 62
Range 38-88 38-81 38-77
Smoking history
Never smokers 63 61 40 60 27 69
Former smokers 8 8 5 8 4 10
Current smokers 32 31 21 32 8 21
Stage
IIIB 30 29 17 26 11 28
IV 73 71 49 74 28 72
Number of sites of metastases
1 16 16 18 27 9 23
2 25 24 26 39 13 33
≥3 62 60 22 34 17 44
CNS metastases
Yes 14 14 12 18 7 18
No 89 86 54 82 32 82
Previous surgery on primary
Yes 46 45 20 30 14 36
No 57 55 46 70 25 64
Previous (neo-)adjuvant CT
Yes 9 9 5 8 4 10
No 94 91 61 92 35 90
Previous adjuvant RT
Yes 4 4 2 4 3 8
No 99 96 63 96 36 92
First-line CT regimen
Platinum + Paclitaxel 10 10 10 15 5 13
Platinum + Gemcitabine 39 39 39 59 21 54
Platinum + Pemetrexed 13 13 13 20 6 15
Cisplatin + Vinorelbine 2 2 2 3 1 3
Cisplatin-based triplet CT 2 2 2 3 2 5
Single-agent CT* 26 26 - - 4 10
Best supportive care only 8 8 - - - -
Anti-EGFR TKI treatment line
2 28 27 24 36 27 69
≥3 12 12 9 14 12 31
Abbreviations: TKIs tyrosine-kinase inhibitors, ECOG Eastern Cooperative Oncology Group, CNS central nervous system, CT chemotherapy, RT radiotherapy.
*Single agent platinum, gemcitabine, vinorelbine, pemetrexed.
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None of the investigated clinical features was signifi-
cantly associated with PFS in patient treated with erlo-
tinib (Table 3).EGFR mutations were significantly correlated with RR
to salvage anti-EGFR TKI (mutant vs. wild-type: 60% vs.
12.5%; p = 0.004) and longer median PFS (mutant vs. wild-
type: 11.4 vs. 4.5 months; HR 0.491, 95% CI 0.216-0.936;
Table 2 EGFR and K-Ras mutational status
Descriptive cohort (n = 103) Correlative cohort (n = 66) Anti-EGFR treated (n = 39)
n % n % n %
EGFR mutational status
Wild-type 72 70 47 71 24 62
Mutant 31 30 19 29 15 38
Sites of EGFR mutation
Exon 19 deletion 24 77* 14 74* 12 80*
E746_A750del 19 62* 10 54* 8 52*
E746_R748del 1 3* 1 5* - -
E746_E749 > Y 1 3* 1 5* 1 7*
L747_A750 > P 1 3* 1 5* 1 7*
L747_T751del 1 3* 1 5* 1 7*
S751_I759del 1 3* - - 1 7*
Exon 20 mutation 3 10* 2 10* - -
G796D 2 7* 1 5* - -
A767_V769dup 1 3* 1 5* - -
Exon 21 mutation 4 13* 3 16* 3 20*
L858R 4 13* 3 16* 3 20*
K-Ras mutational status
Wild-type 76 73 46 70 30 77
Mutant 13 13 9 14 4 10
Not evaluable 14 14 11 16 5 13
Sites of K-Ras mutation
Codon 12 mutation 10 77* 7 78* 4 100*
G12C 6 46* 4 44* 3 75*
G12D 1 8* - - - -
G12V 3 23* 3 34* 1 25*
Codon 13 mutation 3 23* 2 22* - -
G13D 3 23* 2 22* - -
*Calculated as % of total EGFR and K-Ras mutations in each patient cohort.
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proved OS among mutant patients compared to wild-
type ones (21.0 vs. 9.2 months, respectively; HR 0.560,
95% CI 0.231-1.156; p = 0.131).
PFS of K-Ras mutant women treated with salvage anti-
EGFR TKI was significantly reduced compared to that of
wild-type ones receiving the same drug (median: 3.5 vs.
8.8 months; HR 0.284, 95% CI 0.015-0.510; p = 0.010)
(Figure 2B). None of the patients harboring a K-Ras mu-
tant tumor achieved an objective response to erlotinib
compared with 10 out of 30 wild-type patients evaluable
for the analysis (RR: 0% vs. 33%; p = 0.296): of these
10 K-Ras wild-type patients, 8 harbored an EGFR mu-
tant tumor. Of the two groups identified by K-Ras ana-
lysis, significantly shorter OS results were also reported
in the mutant subset (median: 3.9 vs. 19.8 months in wild-
type patients; HR 0.158, 95% CI 0.001-0.075; p < 0.001).Discussion
We retrospectively evaluated the outcomes of Caucasian
women with lung adenocarcinoma, undergoing first-line
platinum-based CT and subsequent salvage anti-EGFR TKI
therapy, in relation to EGFR and K-Ras mutational status.
The clinical selection we applied (i.e. by gender and
histology), together with the high percentage of never
smokers in our series, is probably responsible for the
high incidence of EGFR mutations (30%) and the low
frequency of K-Ras mutations (13%) observed. As ex-
pected, K-Ras mutations were more frequent in current
smokers, while a formally significant influence of smoking
habits on the EGFR mutation rate was not detected: this
was probably due to the small sample size and the poten-
tial confounding effect of other clinical selection criteria,
such as gender and histology. In our series no patient had
concomitant EGFR and K-Ras mutations.
Figure 1 Progression--‐free survival (PFS) with CT according to molecular parameters. A. Progression-free survival (PFS) according to EGFR
status among patients treated with first-line platinum-based combinations. B. Progression-free survival (PFS) according to K-Ras status among
patients treated with first-line platinum-based combinations.





Median p Median p
Smoking history 0.246 0.238
Never smokers 5.0 3.2
Former smokers 5.0 5.6





<70 years 5.5 7.2
≥70 years 6.5 5.0
EGFR mutation* 0.373 0.052
Exon 19 mutation 4.4 12.7
Exon 20 mutation 8.0 NA
Exon 21 mutation 3.2 1.4
Abbreviations: PFS progression-free survival, NA not applicable. *Analysis is
restricted to EGFR mutant patients only.
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ing to clinical characteristics and physicians’ choice.
Retrospectively, the correlation between clinical parame-
ters (RR, PFS and OS) and EGFR and K-Ras mutational
status showed that women with EGFR mutant tumor
achieved a marginally lower RR to first-line platinum-
based combination (32% vs. 43%; p = 0.579) and a signifi-
cantly shorter PFS (4.4 vs. 6.4 months; HR 0.597;
p = 0.048) compared to those with wild-type disease.
There was no impact of the type of EGFR mutations on
the PFS results and, as observed by previous reports,
K-Ras mutations did not play a role in predicting the
benefit from standard CT [16]. The effect of EGFR status
on the efficacy of first-line platinum-based CT has been
only rarely reported in the majority of studies and always
with conflicting results [12]. The most recent and reliable
data may be derived from trials of first-line CT vs. anti-
EGFR TKIs or CT plus a third targeted agent in molecu-
larly unselected patients [8]. However, none of the
reported analyses demonstrated a significant impact of
EGFR mutational status on the benefit from first-line
platinum-containing CT. Looking at the published or
presented results, most trials suggest no role or, at best,
Figure 2 Progression--‐free survival (PFS) with anti--‐EGFR TKI according to molecular parameters. A. Progression-free survival (PFS)
according to EGFR status among patients treated with anti-EGFR TKI. B. Progression-free survival (PFS) according to K-Ras status among patients
treated with anti-EGFR TKI.
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tumor when treated with first-line CT [8,12]. However,
this remains an open issue and a definitive answer cannot
be given since it would, in any case, suffer from several
limitations (e.g., no gender selection, retrospective and
unplanned nature of the analyses). Our series included
only women with lung adenocarcinoma: female gender is
an established good prognostic factor in NSCLC inde-
pendently of disease stage, molecular status and treatment
[20] and we cannot exclude a potential synergistic effect
of gender and EGFR mutational status on the results we
reported. Clinical enrichment in our study could also be
the cause of the interesting median OS we observed (up
to 29.5 months), not always reached in a population of un-
selected advanced NSCLC patients. However, although
limited in size, our results further confirm the need of an
upfront molecular characterization of all patients with
lung adenocarcinoma before starting first-line treatment.
In our series 5 patients with EGFR mutant disease died
without receiving any anti-EGFR treatment, mainly
because of a rapid worsening of performance status due to
disease progression after first-line CT. Considering the
huge amount of data supporting the superiority of anti-
EGFR TKIs compared with CT in these patients, everyeffort should be made to clarify the molecular profile of a
lung adenocarcinoma before starting any treatment in
everyday clinical practice.
Thirty-nine women received salvage erlotinib irrespec-
tively of EGFR or K-Ras mutational status. EGFR muta-
tions are a recognized predictive biomarker [11] and a
regulatory requirement for the use of an anti-EGFR TKI
as first-line approach [21]. Therefore, it is not surprising
that, in our series, the benefit from erlotinib administered
at progression was restricted to EGFR mutant cases both
in terms of RR (p = 0.004) and PFS (HR 0.491; p = 0.044).
Moreover, women with EGFR mutant tumor treated with
front-line CT and salvage anti-EGFR TKI showed a trend
toward a better OS in comparison with those affected by
EGFR wild-type tumor undergoing the same sequence
(HR 0.560; p = 0.131). We might speculate that the dis-
advantage in PFS obtained with first-line CT in EGFR mu-
tated women can be counterbalanced by the better results
achieved with salvage anti-EGFR TKI. However, since a
significant proportion of women with EGFR mutant tu-
mors received no anti-EGFR TKI after first-line CT, once
again we believe that these results stress the importance
of a pre-specified sequence of approaches (upfront TKI
followed by salvage CT) in women harboring molecularly-
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The lack of any impact of the type of EGFR mutation on
PFS could be due, at least in part, to the limited number
of cases in our series.
In our clinically enriched population K-Ras mutations
were not predictive of benefit from CT. As a matter of fact
no difference in RR (33% vs. 39%) and PFS (5.0 vs.
5.3 months) was observed between patients with K-Ras
mutant tumor and those with wild-type disease. The most
recent report in a similar setting (i.e. EGFR wild-type pa-
tients treated with erlotinib after progression to first-line
CT) was the retrospective evaluation of K-Ras status in
the TAILOR study [22]. In this randomized phase III trial
K-Ras mutations were neither prognostic nor predictive of
benefit from docetaxel and no significant interaction was
demonstrated between K-Ras status and PFS or OS.
On the contrary, our results seem to suggest a putative
negative predictive significance of K-Ras mutations for anti-
EGFR TKI activity. None of the patients with K-Ras mutant
tumor achieved an objective response with salvage erlotinib
and these patients experienced a significantly worse median
PFS (HR 0.284; p = 0.010) and OS (HR 0.158; p < 0.001)
compared with patients affected by wild-type NSCLC.
Considering that the benefit from CT did not differ be-
tween the two groups and that K-Ras mutated women ex-
perienced not only a significantly shorter PFS on TKI
but, in particular, a significantly reduced OS, we could
argue that TKI administration in such a population
could be potentially detrimental. However the limited
number of patients in our series prevents us from
drawing any definitive conclusion. Other larger data
sets did not suggest any relevance of K-Ras mutations
in determining the benefit of CT [16], and taking into
account the above mentioned conflicting results about
the predictive role for anti-EGFR TKIs [17,18], we do
not believe that routine K-Ras sequencing should be
considered in all patients with lung adenocarcinoma
outside clinical and translational trials. This is particu-
larly relevant when the tumor is not easily accessible
for biologic sample collection and thus oncologists
need to spare tissue for fundamental analyses, such as
EGFR mutations and EML4-ALK translocation.Conclusions
In our series of Caucasian women with advanced adenocar-
cinoma of the lung EGFR mutations seem to be associated
with lower benefit from first-line platinum-based CT. If
confirmed in larger, prospectively collected, datasets these
results may help to shed light on the potential influence of
gender on EGFR biology in NSCLC. We confirmed that
the presence of an EGFR mutation strongly predicts the
benefit of salvage treatment with erlotinib, stressing the role
of this drug as first-line option in molecularly selectedpatients. The role of K-Ras mutations as biomarkers of
resistance to anti-EGFR TKIs in NSCLC is still unclear and
surely deserves further investigations.
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